Reduced musculoskeletal function and degenerative arthropathy most commonly affects the knees, feet, hands and lower spinal joints. It can manifest in the form of impaired movement, stiffness, swelling and pain, and can result in reduced quality of life and significant social and economic burden. However, questions around an oral dosage of 1200 mg of highly purified chondroitin sulfate (hpCS), efficacy and surrounding costs have remained unclear.
This review involved randomized controlled trials, meta-analyses, systematic reviews and review articles on hpCS and degenerative arthropathy published between 1992 and 2020. The data supported hpCS as an effective and safe compound to help improve musculoskeletal function and act on structural changes. It was seen to have a positive effect at 30 days of administration, and no side effects were reported. Its beneficial action was even seen to be prolonged, as results were maintained for 3 months after hpCS was discontinued. Dosages of 400, 800 and 1200 mg were extensively studied. This use of hpCS also proved to be cost-effective up to a period of 24 months.
Related Biotics Research Products: